Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat
given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer
(NSCLCA) brain metastases in patient with 1-4 lesions.